Akums Drugs & Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 07 Feb 2025
Result Summary
- Akums Drugs & Pharmaceuticals Ltd reported a 2.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 6.1%.
- Its expenses for the quarter were down by 2.1% QoQ and 9.2% YoY.
- The net profit decreased 0.5% QoQ and decreased 66.0% YoY.
- The earnings per share (EPS) of Akums Drugs & Pharmaceuticals Ltd stood at 4.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1024.97 | 1046.56 | 1091.75 | -2.1% | -6.1% |
Total Expenses | 938.70 | 958.66 | 1033.39 | -2.1% | -9.2% |
Profit Before Tax | 91.05 | 91.59 | 59.28 | -0.6% | 53.6% |
Tax | 24.74 | 24.94 | -135.72 | -0.8% | -118.2% |
Profit After Tax | 66.31 | 66.65 | 195.00 | -0.5% | -66.0% |
Earnings Per Share | 4.30 | 4.40 | 0.00 | -2.3% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Akums Drugs & Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for its comprehensive range of products and services. The company specializes in the manufacturing of pharmaceutical formulations in various forms including tablets, capsules, syrups, dry syrups, and injectables. Akums is a significant contract manufacturer for many well-known pharmaceutical brands, providing services from product development to manufacturing and distribution. Recent developments in the industry, such as regulatory changes and innovations in drug manufacturing, may impact companies like Akums, although specific recent developments for Akums are not detailed here.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Akums Drugs & Pharmaceuticals Ltd reported a total income of ₹1024.97 crores. This represents a decrease of 2.1% from the previous quarter (Q2FY25), where the total income was ₹1046.56 crores. Compared to the same quarter in the previous year (Q3FY24), where the total income stood at ₹1091.75 crores, there is a year-over-year decline of 6.1%. These figures reflect changes in the revenue generated by the company over the respective periods.
Profitability
The company recorded a profit before tax of ₹91.05 crores in Q3FY25, which is a slight decrease of 0.6% from ₹91.59 crores in Q2FY25. However, when compared year-over-year, there is a significant increase of 53.6% from Q3FY24, where the profit before tax was ₹59.28 crores. The tax expenses for Q3FY25 were ₹24.74 crores, showing a minimal decrease of 0.8% from the previous quarter. Notably, the profit after tax for Q3FY25 was ₹66.31 crores, marginally down by 0.5% from Q2FY25, but it marks a substantial decline of 66.0% from Q3FY24, when it was ₹195.00 crores. The earnings per share also saw a reduction from ₹4.40 in Q2FY25 to ₹4.30 in Q3FY25.
Operating Metrics
The total expenses for Akums in Q3FY25 were ₹938.70 crores, which shows a 2.1% decrease from ₹958.66 crores in the previous quarter. Comparing year-over-year, there is a 9.2% reduction from the expenses of ₹1033.39 crores in Q3FY24. These expenses are crucial in understanding the operational efficiency of the company across different periods. The decline in both total income and expenses in consecutive quarters suggests changes in the company's operational scale or cost management strategies. The consistent decrease in expenses over the year may reflect measures taken by the company to enhance its cost efficiency.
